<DOC>
	<DOC>NCT02144948</DOC>
	<brief_summary>This is a pilot study to investigate the effect of e.-coli-nissle as supporting therapy to antidiabetic standard care in patients with diabetes mellitus type II</brief_summary>
	<brief_title>Investigation of the Effect of E.-Coli-Nissle as Supporting Therapy to Standard Care of Diabetes Mellitus Type II</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>diabetes mellitus type 2; HbA1c &gt;7 % (stable für 6 months, max. variation of 0,5%) stable oral antidiabetic therapy for 6 months with Metformin, Vildagliptin, Gliniden or without oral Antidiabetics age of 45 to &lt;80 years (men and women) Myocardial infarction or stroke within the last 5 years Therapy with acarbose Acute peripheral arterial disease within the last 12 months Instable metabolic situation Uncontrolled hypertension BodyMassIndex ≥ 35 kg/m² Smokers Daily consumption of probiotic food Malignant disease within the last 5 years Status post transplantation Immunosuppressive therapy within the last 3 months Therapy with antibiotics Macroalbuminuria Severe liver disease</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>diabetes</keyword>
</DOC>